Molecular Modelling and Bioinformatics news

<p>The DNAzyme 9DB1, whose catalytically active structure and reaction mechanism was unknown, makes use of a mechanism involving two ions, similar to that used by natural enzymes (J. Aranda, IRB Barcelona).</p>
20 Jun 2019

Modesto Orozco’s lab (IRB Barcelona) has published a study on the reaction mechanism of DNAzymes in Nature Catalysis.

DNAzymes, which are catalysers formed by DNA, have applications in biomedicine and biotechnology. These research results will contribute to advances in the design and improvement of catalysers for therapeutic purposes.

<p>The asymmetry of DNA-RNA hybrids can be used to improve the efficiency of gene editing technologies like CRISPR-Cas9 (M Terrazas, IRB Barcelona)</p>
13 Jun 2019

Modesto Orozco’s laboratory (IRB Barcelona) has published a study on the source of asymmetry between nucleic acid hybrid (RNA and DNA) in CHEM (Cell Press).

The results are a promising step towards enhancing gene therapies, which are applicable to many diseases.

<p>Illustrated view of the different conformations adopted by a flexible small molecule. Colours represent different ensembles of conformations.</p>
6 Jun 2019

A study done by scientists at IRB Barcelona can simulate and predict the shape of a molecule in function of its environment.

These results mark a milestone for the computational design of molecules with specific shape and features for agrochemical, technological and pharmaceutical applications.

<p>Structure of EGFR. Purple indicates the region recognised by mAB806. Laura Orellana.</p>
3 May 2019

ABC has published an article on a study led by Modesto Orozco, head of the Molecular Modelling and Bioinformatics Lab at IRB Barcelona. This work has unravelled the mechanism of action of the mAb806 antibody, a drug used to treat glioblastoma. Published in the journal PNAS, the study lays the foundation for the extension of this treatment to more types of tumours and to more specific therapies.

Link to ABC

<p>Structure of EGFR. Purple indicates the region recognised by mAB806. Laura Orellana.</p>
2 May 2019

The antibody mAb806 is used to treat glioblastoma, although its mechanism of action has been unknown until now. 

The study, published in the journal PNAS, paves the way to extend treatment with mAb806 to more types of tumours and to the development of more personalised therapies. 

<p>Source: La Diaria</p>
14 Feb 2019

The Uruguayan newpaper La Diaria has published an article about recent research done by the Molecular Modelling and Bioinformatics Lab at IRB Barcelona. This team has achieved the first stable simulations of DNA crystals, thus allowing the study of the role of each molecular component in the stability and conformation of said crystals. The article includes quotes by Pablo Dans, a postdoctoral researcher at the centre, about the study: "What we want is to see how 3D DNA folding occurs and understand how it correlates with the activity of a specific gene. This kind of work has a great plus in that you can see the DNA structure inside the nucleus, and you can manipulate it in three...

<p>Picture of the three crystal systems examined in this study. These systems contain (from left to right) 27, 24 and 36 double-stranded DNA respectively. Pablo Dans Puiggròs, IRB Barcelona.</p>
21 Jan 2019

The breakthrough made by researchers at IRB Barcelona allows the study of the role of each molecular component in the stability and conformation of DNA crystals.

The new molecular simulation techniques are expected to reduce the time and cost of obtaining crystals in the laboratory.

<p>Scheme of the intracellular processing of the 2shRNAs by the activity of Dicer enzyme, producing two independent fragments of shRNA, one against each target (M Terrazas, IRB Barcelona)</p>
21 Dec 2018

Modesto Orozco’s lab has published a paper in Chemical Communications about a therapeutic tool to prevent treatment resistance in breast cancer.

The tool has been tested in tumour cells in vitro and will now need to be tested in animal models before moving on to the development of a valid treatment for patients.

<p>European Research Council (ERC)</p>
15 May 2018

La Razón newspaper has published an article on the grants given by the European Research Council (ERC) to five researchers in Barcelona. Among these grants is the ERC Proof of Concept that Modesto Orozco, head of the Molecular Modelling and Bioinformatics Lab at IRB Barcelona, has received. This grant will allow him to optimise and validate "2shRNA", a tool that can simultaneously attack two therapeutic targets involved in drug resistance pathways and that can also bind to other molecules to enhance their delivery and efficacy.

Link to...

<p>Modesto Orozco, head of the Molecular Modelling and Bioinformatics Lab at IRB Barcelona</p>
11 May 2018

ABC, El Economista, Cope, among other media, have published articles about the ERC Proof of Concept grant awarded to Modesto Orozco, head of the Molecular Modeling and Bioinformatics Lab at IRB Barcelona, to combat resistance in breast cancer.

Link to ABC

Link to El Economista

Link to...